Core Viewpoint - Kangzheng Pharmaceutical (00867) has signed an exclusive distribution agreement for Lidoderm® (lidocaine gel patch) with Teikoku Pharma USA, Inc., granting the company exclusive rights to distribute the product in mainland China for a period of ten years, with potential for renewal [1] Group 1: Product and Market Overview - Lidoderm is a topical patch that blocks voltage-gated sodium channels, reducing pain for patients with postherpetic neuralgia (PHN) [2] - The product was approved by the FDA in 1999 and has shown significant efficacy, with approximately 25% to 33% of patients experiencing at least 50% pain relief in clinical studies lasting 4 to 12 weeks [2] - PHN is a common complication of shingles, with a prevalence that increases with age; about 30% to 50% of patients may experience pain lasting over one year, and in China, it is estimated that there are around 4 million PHN patients [3] Group 2: Company and Partner Profile - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products in pain management and dermatology [4] - Teikoku Seiyaku is one of the largest manufacturers of hydrogel patches and has a diverse portfolio of over 200 prescription and over-the-counter products distributed in more than 50 countries [4] Group 3: Strategic Implications for Kangzheng Pharmaceutical - The introduction of Lidoderm enhances Kangzheng's product portfolio and is expected to create synergies with existing products, leveraging expert resources and marketing channels [5] - The company aims to expand its presence in the outpatient market and develop a comprehensive commercial ecosystem that integrates online and offline channels [5] - The board believes that the terms of the agreement are fair and reasonable, aligning with the overall interests of the company and its shareholders [5]
康哲药业(00867)：签订原研药Lidoderm®利多卡因凝胶贴膏独家经销协议